We areworking relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients
We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients
Pipeline
Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.
| Preclinical | Clinical | Marketed | |||||
| Indication | Proof of Principle | Safety | Dose Optimization | Clinical Activity | Pivotal | Commercial | |
|---|---|---|---|---|---|---|---|
| Heme Malignancies | |||||||
| CA-4948* IRAK4 |
MYD88/TLR-altered Lymphoma (NHL) | ||||||
| CA-4948* IRAK4 |
IRAK4L-expressing Leukemia (AML/MDS) | ||||||
| Fimepinostat HDAC/PI3K |
MYC-altered Cancers | ||||||
| Immune Checkpoint Inhibitors | |||||||
| CI-8993** VISTA |
VISTA-expressing Cancers | ||||||
| CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | ||||||
| CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | ||||||
| Approved Drug | |||||||
| Erivedge*** Hedgehog |
Basal Cell Carcinoma | ||||||
| Drug | Indication | Stage |
| Heme Malignancies | CA-4948* IRAK4 |
MYD88/TLR-altered Lymphoma (NHL) | Clinical Activity |
| CA-4948* IRAK4 |
IRAK4L-expressing Leukemia (AML/MDS) | Safety |
| Fimepinostat HDAC/PI3K |
MYC-altered Cancers | Clinical Activity |
| Immune Checkpoint Inhibitors | CI-8993** VISTA |
VISTA-expressing Cancers | Safety |
| CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | Proof of Principle |
| CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | Clinical Activity |
| Approved Drug | Erivedge*** Hedgehog |
Basal Cell Carcinoma | Commercial |
* IP licensed from Aurigene
** Option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)